The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to NP-G2-044, an experimental treatment for pancreatic cancer that’s currently in clinical…
News
Treatment with DeltEx DRI, a cell therapy developed by In8bio, is prolonging survival outcomes among people with newly diagnosed glioblastoma in a clinical…
GYNECOLOGICAL CANCER
Oral treatment for ovarian cancer put on FDA fast track
The U.S. Food and Drug Administration (FDA) has granted fast track designation to ETX-19477, an oral treatment for ovarian cancer currently in early clinical testing.
Johnson & Johnson is now seeking regulatory approval in the European Union for Tecvayli (teclistamab) plus Darzalex Faspro (daratumumab and hyaluronidase-fihj) for…
All four adults with hard-to-treat acute myeloid leukemia (AML) who received treatment with a combination of Venclexta (venetoclax) and AB Science‘s experimental therapy AB8939…
PANCREATIC CANCER
FDA grants orphan drug status to ARB1002 for pancreatic cancer
A new experimental treatment for pancreatic cancer, ARB1002, has been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA) and…
TTX-MC138, an RNA-based therapy from Transcode Therapeutics that’s in early clinical development, induced tumor cell death and prolonged survival in a mouse model of…
GYNECOLOGICAL CANCER
Ernexa’s stem cell therapy could soon enter ovarian cancer trials
Ernexa Therapeutics is making headway on plans to start clinical testing of ERNA-101, its stem cell therapy designed to treat ovarian cancer. The U.S.
Medications designed to block a signaling protein called NOTCH3 — which plays a key role in the function and survival of cells in the body…
A Phase 3 clinical trial testing the experimental cancer vaccine galinpepimut-S (GPS) in people with acute myeloid leukemia (AML), a type of blood cancer,…
Recent Posts
- FDA to review glioma imaging agent, sets September decision date
- I’m taking up walking to combat the fog of ‘chemo brain’
- FDA OKs first-in-human trial of cell therapy for hard-to-treat AML
- First-of-its-kind solid tumor cell therapy prepares to debut in China
- Patients and caregivers can tap into the power of humor, too
